Stock listing

Shanghai:600521 Zhejiang Huahai Pharmaceutical Co., Ltd. (华海药业) 股价

Follow Zhejiang Huahai Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.

Share price · SSE:600521

¥15.56 CNY -0.92 (-5.6%)

Close on Nov 20, 2026

Past year -11.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
¥15.45 – ¥16.32 CNYNov 20, 2026
Volume
28.31M sharesNov 20, 2026
Market cap
¥23.30B CNYAt the close on Nov 20, 2026 · price × 1.50B shares outstanding
52-week range
¥13.73 – ¥18.88 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
¥444.4M CNYMedian day 22.66M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Zhejiang Huahai Pharmaceutical Co., Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:600521 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥15.56-0.92-5.6%¥16.16¥16.32¥15.4528,308,800
¥16.48-0.13-0.8%¥16.61¥16.72¥16.1016,945,936
¥16.61+0.09+0.5%¥16.45¥16.79¥16.3513,800,333
¥16.52-0.28-1.7%¥16.87¥16.90¥16.4814,222,579
¥16.80-0.26-1.5%¥16.98¥17.09¥16.7017,353,382
¥17.06-0.17-1.0%¥17.23¥17.35¥16.9821,711,452
¥17.23-0.10-0.6%¥17.29¥17.41¥17.1816,717,457
¥17.33+0.01+0.1%¥17.48¥17.53¥17.2717,421,591
¥17.32-0.29-1.6%¥17.66¥17.82¥17.2821,262,548
¥17.61-0.26-1.5%¥17.44¥17.90¥17.4326,079,447
¥17.87+0.89+5.2%¥16.92¥17.93¥16.9253,216,681
¥16.98+0.47+2.8%¥16.51¥17.08¥16.5036,725,333
¥16.51+0.01+0.1%¥16.50¥16.69¥16.3118,210,807
¥16.50+0.24+1.5%¥16.39¥16.62¥15.9429,979,543
¥16.26+0.36+2.3%¥15.85¥16.72¥15.6634,449,194
¥15.90-0.30-1.9%¥16.21¥16.26¥15.7323,423,597
¥16.20+0.17+1.1%¥16.15¥16.39¥16.0619,556,308
¥16.03-0.70-4.2%¥16.79¥16.92¥16.0333,596,696
¥16.730.000.0%¥16.65¥16.96¥16.6021,324,378
¥16.73+0.60+3.7%¥15.87¥16.77¥15.8130,529,627
¥16.13-0.51-3.1%¥16.59¥16.59¥16.1325,461,033
¥16.64-0.10-0.6%¥16.81¥16.95¥16.6229,912,119
¥16.74+0.08+0.5%¥16.60¥16.78¥16.4025,083,208
¥16.66+0.15+0.9%¥16.40¥16.80¥16.3126,361,194
¥16.51+0.02+0.1%¥16.67¥17.19¥16.3440,090,352
¥16.49-0.01-0.1%¥16.22¥16.80¥16.1233,688,230
¥16.50-0.37-2.2%¥16.80¥16.81¥16.3927,416,595
¥16.87-0.01-0.1%¥16.75¥17.12¥16.5141,845,360
¥16.88-0.57-3.3%¥17.49¥17.49¥16.8641,711,422
¥17.45+0.80+4.8%¥16.77¥17.46¥16.5872,199,528
¥16.65+0.31+1.9%¥17.00¥17.10¥16.5661,239,685
¥16.34+0.35+2.2%¥15.97¥16.46¥15.8921,244,737
¥15.99+0.08+0.5%¥15.91¥16.38¥15.8218,838,722
¥15.91+0.03+0.2%¥15.87¥16.11¥15.8214,331,717
¥15.88-0.53-3.2%¥16.22¥16.43¥15.7527,338,946
¥16.41-0.16-1.0%¥16.50¥16.63¥16.3317,316,859
¥16.57-0.09-0.5%¥16.61¥16.75¥16.4521,793,719
¥16.66+0.52+3.2%¥16.18¥16.71¥16.1834,973,650
¥16.14-0.21-1.3%¥16.35¥16.56¥16.1318,886,806
¥16.35+0.14+0.9%¥16.10¥16.60¥16.0922,398,747
¥16.21+0.69+4.4%¥15.63¥16.42¥15.4536,491,509
¥15.52-0.10-0.6%¥15.51¥15.65¥15.4710,148,015
¥15.62+0.25+1.6%¥15.36¥15.65¥15.2913,957,462
¥15.37-0.17-1.1%¥15.51¥15.59¥15.1515,770,288
¥15.54-0.34-2.1%¥15.78¥15.87¥15.4517,899,325
¥15.88-0.01-0.1%¥15.81¥15.93¥15.7411,067,222
¥15.89+0.14+0.9%¥15.81¥16.02¥15.6614,663,744
¥15.75-0.24-1.5%¥15.96¥15.96¥15.6319,306,424
¥15.99-0.12-0.7%¥16.10¥16.17¥15.9618,587,700
¥16.11+0.14+0.9%¥15.97¥16.15¥15.8417,100,759
¥15.97-0.23-1.4%¥16.14¥16.24¥15.9619,713,846
¥16.20+0.09+0.6%¥16.10¥16.27¥16.0121,896,005
¥16.11-0.35-2.1%¥16.35¥16.35¥15.9327,485,883
¥16.46-0.18-1.1%¥16.60¥16.67¥16.3321,897,987
¥16.64+0.24+1.5%¥16.44¥16.88¥16.4132,167,729
¥16.40-0.03-0.2%¥16.36¥16.66¥16.2022,921,084
¥16.43+0.23+1.4%¥16.08¥16.45¥15.8828,734,377
¥16.20-0.42-2.5%¥16.51¥16.66¥15.9036,500,123
¥16.62-0.75-4.3%¥17.06¥17.10¥16.4850,559,380
¥17.37+0.22+1.3%¥17.50¥17.93¥17.1756,253,772

Splits

9 splits since 2004 · SSE:600521 · every price before a split is adjusted for it

DayRatioWhat
11-for-10Split
6-for-5Split
13-for-10Split
13-for-10Split
6-for-5Split
3-for-2Split
13-for-10Split
13-for-10Split
9-for-5Split
Ticker
Shanghai:600521
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Shanghai
Currency
CNY

What changed lately

Latest news

All Zhejiang Huahai Pharmaceutical Co., Ltd. news

Zhejiang Huahai Pharmaceutical Co., Ltd. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
70 in the last 12 months · 76 in all · newest Nov 6, 2026 · oldest 2025

Valuation

P/E 24.6× against a median of 17.4×: 8th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥24.34B CNY
P/E
24.6×
EV/sales
2.5×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.3×
Gross margin
58.7%
Operating margin
15.5%
Net margin
9.8%
Debt to equity
0.3×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Zhejiang Huahai Pharmaceutical Co., Ltd. Class A · SSE:600521US$3.49BUS$3.65B24.6×2.5×n/a2.3×9.8%0.3×n/a
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A · SZSE:002603US$3.72BUS$3.34B18.0×2.8×n/a2.2×17.4%0.0×n/a
Organon & Co. · NYSE:OGNUS$3.65BUS$10.75B17.1×1.8×n/a3.1×3.5%7.2×0.52
Tarsus Pharmaceuticals, Inc. · NASDAQ:TARSUS$3.60BUS$3.36Bn/a4.9×n/a34.6×−102.9%0.7×0.62
Laboratorios Farmaceuticos Rovi, S.A. · BME:ROVIUS$3.54BUS$3.52B17.4×4.2×15.8×4.6×23.9%0.1×n/a
China Resources Pharmaceutical Group Ltd. · HKEX:3320US$3.51BUS$14.02B5.2×0.3×5.1×0.4×1.5%1.9×n/a
Orion Oyj Class A · OMXHEX:ORNAVUS$3.42BUS$3.40B4.7×1.4×3.5×2.2×30.3%0.1×n/a
Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A · SZSE:002262US$3.41BUS$2.79B20.8×3.0×n/a2.6×17.7%0.0×n/a
Beijing Tiantan Biological Products Corporation Limited Class A · SSE:600161US$3.39BUS$3.10B32.3×3.7×n/a1.9×12.6%0.0×n/a
Arcutis Biotherapeutics, Inc. · NASDAQ:ARQTUS$3.33BUS$3.18B111×6.3×85.1×13.7×5.9%0.5×1.38
Simcere Pharmaceutical Group Limited · HKEX:2096US$3.32BUS$3.08B16.5×2.7×10.6×2.4×17.4%0.3×n/a
Median of the othersUS$3.47BUS$3.35B17.4×2.9×10.6×2.5×15.0%0.2×0.62

Forecasts

Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.

Price target
19.67 CNY · Analysts' mean
EPS, year to Dec 2026
0.92 · 1 analyst
Revenue, year to Dec 2026
9.74B · 1 analyst

Events

QuarterResultsShare move
Q2 2026Aug 26, 2026 · After close+1.5%
Q1 2026Apr 29, 2026 · After close+1.8%
Q2 2025Aug 25, 2025 · After close−1.3%
Q1 2025Apr 29, 2025 · After close−0.2%
Q3 2024Oct 30, 2024 · After close−0.9%
Q1 2024Apr 29, 2024 · After close+4.0%
Q3 2023Oct 30, 2023 · After close+0.4%
Q2 2023Aug 30, 2023 · After close−0.5%
Q1 2023Apr 28, 2023 · Before open+0.1%
Q3 2022Oct 28, 2022 · Before open−2.5%
All 15 quarters
QuarterResultsShare move
Q2 2022Aug 30, 2022 · After close+0.3%
Q1 2022Apr 18, 2022 · Before open−1.6%
Quarter to Sep 30, 2021Oct 29, 2021 · Before open−0.4%
Quarter to Jun 30, 2021Aug 26, 2021 · After close−1.7%
Quarter to Mar 31, 2021Apr 25, 2021 · Before open+10.0%

Open Events

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue8.59B9.55B8.31B8.27B6.64B6.49B5.39B5.09B5.00B4.09B
Cost of revenue3.42B3.74B3.38B3.18B2.67B2.38B2.20B2.14B2.20B2.05B
Gross profit5.17B5.81B4.93B5.09B3.97B4.10B3.19B2.95B2.80B2.04B
Research and development1.23B986.7M983.0M925.5M942.3M565.7M467.4M396.8M353.4M364.0M
Selling, general and administrative2.11B1.46B1.30B1.29B1.27B1.08B895.6M839.8M646.6M852.9M
Operating income833.5M1.47B1.12B1.55B868.4M1.29B824.4M475.2M791.2M508.0M
Depreciation and amortization1.01B916.8M789.6M672.0M563.1M470.8M410.7M345.0M289.9M251.0M
EBITDA1.84B2.39B1.91B2.22B1.43B1.76B1.24B820.3M1.08B759.0M
Interest expense233.6M226.1M237.8M223.9M170.7M139.1M234.9M150.4M65.2M45.4M
Income before tax443.9M1.46B1.10B1.51B786.9M1.22B760.9M157.2M779.2M567.1M
Income tax356.1M283.1M332.9M306.3M220.8M154.0M22.3M155.7M110.2M
Net income266.4M1.12B830.5M1.17B487.5M929.8M569.6M107.5M639.2M500.8M
Earnings per share, basic0.180.770.570.800.340.640.390.080.460.37

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents1.50B1.54B1.34B1.37B1.88B2.21B1.50B910.8M691.3M791.6M
Short-term investments76.0M60.8M93.0M143.1M1.01M2.05K
Receivables2.87B3.27B2.68B2.83B1.91B1.76B1.40B1.94B1.66B1.35B
Inventory3.71B3.41B3.43B3.37B2.74B2.37B2.22B2.18B1.59B1.33B
Current assets8.74B8.48B7.62B7.91B6.81B6.52B5.27B5.21B4.07B3.51B
Property, plant and equipment5.96B4.37B3.80B3.52B2.94B2.56B
Goodwill64.4M64.4M64.4M70.9M70.9M70.9M70.9M70.9M70.9M70.9M
Total assets21.5B20.3B18.6B18.2B15.5B13.0B10.7B10.4B8.27B6.73B
Accounts payable1.81B1.59B1.39B1.20B881.8M392.5M577.0M662.6M759.4M175.3M
Current liabilities9.11B5.98B5.45B4.80B4.24B2.89B3.36B4.77B2.84B1.51B
Long-term debt1.84B4.39B4.02B4.64B3.50B2.92B1.18B900.0M222.2M534.7M
Total debt6.52B5.65B6.86B5.63B4.05B3.31B3.55B1.81B1.02B
Total liabilities12.0B11.2B10.3B10.4B8.69B6.27B4.95B6.16B3.21B2.15B
Shareholders' equity9.44B8.90B8.08B7.55B6.56B6.51B5.61B4.07B4.88B4.38B
Shares outstanding1.50B1.45B1.46B1.46B1.45B1.45B1.45B1.31B1.38B1.35B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations1.23B2.17B2.22B1.24B938.4M1.56B1.75B67.9M546.2M433.1M
Capital spending-1.97B-1.85B-1.59B-2.32B-2.43B-1.28B-794.3M-1.12B-794.5M-732.9M
Free cash flow-736.0M319.3M624.6M-1.07B-1.50B279.0M959.6M-1.06B-248.3M-299.8M
Cash from investing-1.92B-1.62B-2.43B-2.36B-1.36B-791.1M-1.26B-1.14B-706.7M
Cash from financing-132.9M-644.2M609.0M1.12B596.3M-400.3M1.35B556.6M408.8M
Dividends paid-546.2M-475.4M-556.0M-147.3M-290.9M-392.8M-208.9M-308.0M-241.6M-194.4M
Share buybacks-189.9M-71.0M-172.4M-150.0M-4.75M
Change in cash-31.0M170.6M-21.0M-526.2M-343.6M708.9M591.3M219.6M-74.1M185.9M

Open Financials

Filings

FilingDateTypeFiled with
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Progress in Providing Guarantee for SubsidiaryNov 6, 2026Other filingsShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Results of Redemption at Maturity of "HUAHAI Convertible Bonds" and Share ChangesNov 3, 2026ResultsShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Approval for Drug Clinical Trials by SubsidiaryNov 3, 2026Operations updateShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Report for Q3 2026Oct 30, 2026Quarterly reportShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 18th Extraordinary Meeting of the 9th Board of DirectorsOct 30, 2026Meeting outcomeShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Provision for Asset Impairment for the First Three Quarters of 2026Oct 30, 2026ResultsShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Redemption at Maturity and Delisting of "HUAHAI Convertible Bonds"Oct 23, 2026FinancingShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Drug Registration CertificateOct 20, 2026Other filingsShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Capital Increase and Share Expansion of Controlled Subsidiary for Introduction of InvestorsOct 16, 2026Acquisition or disposalShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 17th Extraordinary Meeting of the 9th Board of DirectorsOct 16, 2026Meeting outcomeShanghai Stock Exchange
All 76 filings
FilingDateTypeFiled with
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 16th Extraordinary Meeting of the 9th Board of DirectorsOct 13, 2026Meeting outcomeShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Capital Increase in Investee Company and Related Party TransactionsOct 13, 2026Acquisition or disposalShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Conversion Results of Convertible Corporate Bonds and Share ChangesOct 9, 2026ResultsShanghai Stock Exchange
(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Estimated Increase in Performance for the First Three Quarters of 2026Oct 8, 2026GuidanceShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Progress in Providing Guarantee for SubsidiarySep 29, 2026Other filingsShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Third Indicative Announcement on Redemption at Maturity and Delisting of "HUAHAI Convertible Bonds"Sep 24, 2026FinancingShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Second Indicative Announcement on Maturity Redemption and Delisting of "HUAHAI Convertible Bonds"Sep 23, 2026FinancingShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."First Indicative Announcement on Maturity Redemption and Delisting of "HUAHAI Convertible Bonds"Sep 22, 2026FinancingShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance BriefingSep 18, 2026Meeting noticeShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Overseas Marketing Authorization for the Formulation ProductsSep 14, 2026Operations updateShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Pledge of Certain Shares Held by the ShareholderSep 10, 2026Other filingsShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Semi-annual Report for 2026Aug 26, 2026Interim reportShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Subsidiary Passing the Drug GMP Compliance InspectionAug 19, 2026Operations updateShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on the Proposed Selection of the Company's Products in the 12th Batch of National Centralized Drug ProcurementAug 2, 2026Operations updateShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on the Signing of the Four-Party Supervision Agreement for Raised FundsJul 29, 2026Material contractShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Approval for Drug Clinical Trials by SubsidiaryJul 24, 2026Operations updateShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Appointment of Senior ManagementJul 15, 2026Management or board changeShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Progress of Authorized Disposal of Financial Assets at an Appropriate TimeJul 13, 2026Acquisition or disposalShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Inclusion of the Company's Products in the National Essential Medicines ListJul 10, 2026Operations updateShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on the Receipt of U.S. Customs Duty RefundJul 8, 2026Other filingsShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Expected Increase in Semi-annual Performance for 2026Jul 5, 2026GuidanceShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Drug Registration CertificateJul 2, 2026Operations updateShanghai Stock Exchange
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Conversion Result of Convertible Bonds and Share ChangesJul 1, 2026FinancingShanghai Stock Exchange
Announcement on Progress in Providing Guarantee for Holding SubsidiaryJun 29, 2026Other filingsShanghai Stock Exchange
Announcement on Resolutions of the 13th Extraordinary Meeting of the 9th Board of DirectorsJun 26, 2026Meeting outcomeShanghai Stock Exchange
Indicative Announcement on Acceptance of the Subsidiary’s Application for Marketing Authorization of DrugsJun 25, 2026Operations updateShanghai Stock Exchange
Announcement on Progress in Arbitration Case Involving the CompanyJun 23, 2026Legal or regulatory actionShanghai Stock Exchange
Announcement on Obtaining Drug Registration Certificate by the Company and Its SubsidiariesJun 15, 2026Operations updateShanghai Stock Exchange
Announcement on Progress in Transfer of Equity in Subsidiary Huahai Tianheng (Shanghai) Pharmaceutical Research Co., Ltd.Jun 12, 2026Acquisition or disposalShanghai Stock Exchange
Announcement on Implementation of Dividend Distribution for 2025Jun 11, 2026DividendShanghai Stock Exchange
Announcement on Obtaining Drug Registration CertificateJun 8, 2026Operations updateShanghai Stock Exchange
Indicative Announcement on Suspending Conversion of "Huahai Convertible Bonds" When Implementing Dividend Distribution for 2025Jun 5, 2026DividendShanghai Stock Exchange
Announcement on Release of Pledge and Re-pledge of Some Shares of ShareholdersJun 4, 2026Other filingsShanghai Stock Exchange
Announcement on Obtaining Approval for Drug Clinical Trials by SubsidiaryJun 2, 2026Other filingsShanghai Stock Exchange
Announcement on Convening Performance Briefing for 2025 and Q1 2026May 26, 2026Meeting noticeShanghai Stock Exchange
Announcement on Resolutions of the 2025 Annual General MeetingMay 21, 2026Meeting outcomeShanghai Stock Exchange
Announcement on Cancellation of Account for Raised FundsMay 20, 2026Other filingsShanghai Stock Exchange
Indicative Announcement on Convening the 2025 Annual General MeetingMay 14, 2026Meeting noticeShanghai Stock Exchange
Announcement on Outline of Open Day for InvestorsMay 11, 2026Other filingsShanghai Stock Exchange
Announcement on Changing Independent Directors and Adjusting Members of Special Committees of Board of DirectorsApr 29, 2026Management or board changeShanghai Stock Exchange
Announcement on Disclosure of the 2025 Annual Report by the Holding Subsidiary, Changxing Pharmaceutical Co., Ltd.Apr 28, 2026Annual reportShanghai Stock Exchange
Announcement on the Return of Raised FundsApr 24, 2026FinancingShanghai Stock Exchange
Announcement on Holding Open Day Activities for InvestorApr 21, 2026Other filingsShanghai Stock Exchange
Announcement on Resolutions of the 10th Extraordinary Meeting of the 9th Board of DirectorsApr 17, 2026Meeting outcomeShanghai Stock Exchange
Earnings Preannouncement for Q1 2026Apr 14, 2026ResultsShanghai Stock Exchange
Indicative Announcement on Expected Trigger of Downward Revision for the Conversion Price of ""Huahai Convertible Bonds"Apr 10, 2026FinancingShanghai Stock Exchange
Announcement on Conversion Result of Convertible Corporate Bonds and Share ChangesApr 1, 2026Other filingsShanghai Stock Exchange
Announcement on Resolutions of the 9th Extraordinary Meeting of the 9th Board of DirectorsMar 27, 2026Meeting outcomeShanghai Stock Exchange
Announcement on Resolutions of the 8th Extraordinary Meeting of the 9th Board of DirectorsMar 20, 2026Meeting outcomeShanghai Stock Exchange
Announcement on Maturity of Partial Idle Raised Funds Used for Cash ManagementMar 19, 2026Other filingsShanghai Stock Exchange
Announcement on Subsidiary HB0025 Injection Initiating Endometrial Cancer Phase III Clinical TrialMar 18, 2026Operations updateShanghai Stock Exchange
Announcement on Obtaining the U.S. FDA Approval for the Product Gabapentin CapsulesMar 10, 2026Operations updateShanghai Stock Exchange
Announcement on Obtaining Drug Registration Certificate by SubsidiaryMar 9, 2026Other filingsShanghai Stock Exchange
Announcement on Progress in Legal Proceedings Involving the Company and Its SubsidiariesFeb 27, 2026Legal or regulatory actionShanghai Stock Exchange
Announcement on Obtaining the Notice on Approval of Drug Supplement ApplicationFeb 3, 2026Other filingsShanghai Stock Exchange
Announcement on Expected Decrease in Performance for 2025Jan 26, 2026GuidanceShanghai Stock Exchange
On-Site Inspection Report of Zheshang Securities Co., Ltd. on Continuous Supervision over ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. in 2025Jan 5, 2026Other filingsShanghai Stock Exchange
Announcement on Release of Pledge of Partial Equity of ShareholderDec 31, 2025Other filingsShanghai Stock Exchange
Announcement on Optional Repurchase Results of "Huahai Convertible Bonds"Dec 30, 2025FinancingShanghai Stock Exchange
Announcement on Subsidiary HB0025 Injection Initiating Phase III Clinical TrialDec 26, 2025Other filingsShanghai Stock Exchange
Announcement on Progress in Drug Clinical Trials by SubsidiaryNov 19, 2025Operations updateShanghai Stock Exchange
Announcement on Convening the Q3 2025 Performance BriefingNov 10, 2025Meeting noticeShanghai Stock Exchange
Announcement on the Subsidiary Passing On-site Inspection by FDANov 6, 2025Operations updateShanghai Stock Exchange
Announcement on Not Revising Downward the Conversion Price of ""HUAHAI Convertible Bonds"Nov 5, 2025FinancingShanghai Stock Exchange
Report for Q3 2025Oct 30, 2025Quarterly reportShanghai Stock Exchange
Announcement on Products Being Prospective Winners in the 11th National Centralized Drug ProcurementOct 28, 2025Operations updateShanghai Stock Exchange

Open Filings

Cap table

Built by 6ix from Zhejiang Huahai Pharmaceutical Co., Ltd. Class A’s releases

Common shares
1,497,253,704
Fully diluted
1,497,253,704

Fully diluted

LineShares
Common shares1,497,253,704

Share count over time

CountShares
Nov 22, 20261,497,253,704

Open Cap table

Shareholders

HolderSharesValueAs of
Vanguard Total International Stock Index Fund1.46MUS$3.61MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund1.41MUS$3.5MJul 31, 2026
Emerging Markets Core Equity 2 Portfolio297KUS$735KJul 31, 2026
WisdomTree Emerging Markets SmallCap Dividend Fund277KUS$587KJun 30, 2026
Vanguard Ftse All-World Ex-Us Index Fund266KUS$659KJul 31, 2026
Dimensional Emerging Markets Value Fund248KUS$613KJul 31, 2026
Schwab Emerging Markets Equity ETF140KUS$331KMay 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF104KUS$257KJul 31, 2026
Dimensional Emerging Core Equity Market ETF90,500US$224KJul 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF79,610US$197KJul 31, 2026
All 30 holders
HolderSharesValueAs of
The Emerging Markets Series77,640US$192KJul 31, 2026
Vanguard Total World Stock Index Fund77,340US$192KJul 31, 2026
State Street(R) SPDR(R) S&P(R) China ETF47,454US$101KJun 30, 2026
Parametric Emerging Markets Fund41,250US$102KJul 31, 2026
World ex U.S. Core Equity Portfolio32,200US$79,757Jul 31, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF32,100US$68,097Jun 30, 2026
Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF26,520US$62,563May 29, 2026
Vanguard ESG International Stock ETF20,400US$48,084May 31, 2026
JNL Emerging Markets Index Fund15,500US$32,954Jun 30, 2026
Emerging Markets Social Core Equity Portfolio14,810US$36,683Jul 31, 2026
Franklin FTSE China ETF12,200US$25,881Jun 30, 2026
Emerging Markets Targeted Value Portfolio9,700US$24,026Jul 31, 2026
World ex U.S. Targeted Value Portfolio9,500US$23,531Jul 31, 2026
JPMorgan BetaBuilders Emerging Markets Equity ETF7,000US$17,326Jul 31, 2026
Dimensional Emerging Markets Value ETF6,400US$15,845Jul 31, 2026
Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF3,386US$7,992May 29, 2026
Goldman Sachs MarketBeta Total International Equity ETF1,390US$3,281May 29, 2026
BNY Mellon Emerging Markets Equity ETF1,200US$2,974Jul 31, 2026
Goldman Sachs MarketBeta Emerging Markets Equity ETF904US$2,134May 31, 2026
Franklin FTSE Asia ex Japan ETF700US$1,485Jun 30, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about Zhejiang Huahai Pharmaceutical Co., Ltd.